Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in Iron overloaded thalassemia patients

Iranian Red Crescent Medical Journal

Volumn 12, Issue 6, 2010, Pages 655-659

  Tamaddoni, A ^a   Ramezani, M S ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chelation therapy; Deferiprone; Deferoxamine; Thalassemia major

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; INJECTION SITE ABSCESS; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; RANDOMIZATION; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; THALASSEMIA MAJOR; TOXICITY; TREATMENT DURATION; TREATMENT PLANNING;

EID: 78649757861     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Karimi M, Mehrabani D, Pasalar M, Reza Afrasiabi A, Mehravar Z, Reyhani I, Hamidi R. Thalassemia, iron and G6PD deficiency in Lor migrating nomad children, southern Iran. Iran Red Crescent Med J 2010; 12:441-445
2. Brittenham GM. The red cell cycle. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease, WB Saunders Co, London, 1994.
3. Gabutti V, Piga A. Results of longterm iron-chelating therapy. Acta Haematol 1996;95:26-36. [8604584] [doi:10.1159/000203853]
4. Brittenham GM, Griffith PM, Nienhuis W, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-553. [8047080] [doi:10.1056/NEJM199409013310902]
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193. [15477202]
6. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355:2051-2052. [10885361] [doi:10.1016/S0140-6736(00)02357-6]
7. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 2004;104:34-39. [14988152] [doi:10.1182/blood- 2003-09-3167]
8. Emamimoghadam A, Ahmadi F, Kaykhaei B, Zandian K, Pedram M, Farhangi H. Prediction of heart complications in thalassemia major patients. Iran Red Crescent Med J 2010;12:332-333.
9. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1-2- dimethyl- 3-hydroxypyrid-4-1, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-1295. [2884415] [doi:10.1016/S0140-6736(87)90545-9]
10. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 1987;295: 1509-1512. [3122880] [doi:10.1136/bmj.295.6612.1509]
11. Cohen A, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587. [12763939] [doi:10.1182/blood-2002-10-3280]
12. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24. [12637334] [doi:10.1182/blood-2002-06-1867]
13. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and deferoxamine. Br J Haematol 1998;103:361-364. [9827905] [doi: 10.1046/j.1365-2141.1998.01002.x]
14. Grady RW, Berdoukas V, Rachmilewitz E, Galanello R, Borgna-Pignatti C, Giardina PJ. Iron chelation therapy: optimizing chelation therapy: combining deferiprone and deferoxamine. Blood 2000;96:604a [abstract].
15. Breuer W, Ermers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Deferoxamine chelatable iron, a component of serum non-transferrin bound iron, used for assessing chelation therapy. Blood 2001;97:792-798. [11157499] [doi:10.1182/blood.V97. 3.792]
16. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C. A randomized controlled 1- year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007;92: 1599-1606. [18055982] [doi:10.3324/ haematol.11414]
17. Balveer K, Pyar K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia 2000;55:493-497.[11221163]
18. Mourad FH, Hoffbrand AV, Sheikh- Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-189. [12670352] [doi:10. 1046/j.1365-2141.2003.04240.x]
19. Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V, Tsantali H. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica 2004;89:ELT07. [15075120]
20. Farmaki K, Anagnostopoulos G, Platis O, Gotsis E, Toulas P. Combined chelation therapy in patients with thalassemia major: a fast and effective method of reducing ferritin levels and cardiological complications. Hematol J 2002;3:79. [abstract]
21. Alymara V, Bourantas DK, Chaidos A, Hatzimichael EC, Vergos A, Dimos GA, Vassou A, Gouva M. Combined iron chelation therapy with deferoxamine and deferiprone in beta-thalassemic patients. Hematol J 2002;3:81. [abstract]
22. Kattamis, Kassou C, Ladis V, Berdussi H, Papasotiriou I, Kattamis C. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia. Blood 2002;100:120a. [abstract]
23. Grady RW, Berdoukas V, Rachmilewitz EA, Glardina PJ. Iron chelation therapy: Metabolic aspects of combining deferiprone and deferoxamine. 11th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Diseases: Catania, Italy; 2001: pp.74-78 [abstract].
24. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360:516-520. [12241655] [doi:10.10 16/S0140-6736(02)09740-4]
25. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88:489-496. [12745268]
26. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-3744. [16352815] [doi:10.1182/blood-2005-07-2948]
27. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;108:305-312. [10691860] [doi:10.1046/j.1365-2141.2000.01866.x]a